- Home
- RRR vs DNLI Comparison
RRR vs DNLI Comparison
Compare RRR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | DNLI |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RRR | DNLI |
|---|---|---|
| Price | $59.64 | $20.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $69.69 | $34.33 |
| AVG Volume (30 Days) | 740.9K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.62 | $408.85 |
| P/E Ratio | $81.88 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $47.57 | $12.58 |
| 52 Week High | $68.99 | $23.77 |
Technical Indicators
Market Signals| Indicator | RRR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 56.48 |
| Support Level | $55.50 | $17.77 |
| Resistance Level | $63.34 | $22.07 |
| Average True Range (ATR) | 1.93 | 0.94 |
| MACD | 0.41 | 0.07 |
| Stochastic Oscillator | 94.65 | 81.91 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.